Tracing ASCO丨Professor Yongmei Yin: OptiTROP-Breast05 Study Selected for Oral Presentation, Domestic TROP2 ADC Once Again in the Spotlight

Tracing ASCO丨Professor Yongmei Yin: OptiTROP-Breast05 Study Selected for Oral Presentation, Domestic TROP2 ADC Once Again in the Spotlight

Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the phase II OptiTROP-Breast05 study, which evaluated sac-TMT as a first-line therapy for advanced triple-negative breast cancer (TNBC). The results demonstrated impressive efficacy and a favorable safety profile. Oncology Frontier invited Professor Yongmei Yin at the conference to discuss the study's key outcomes and how sac-TMT, as a leading TROP2 ADC, is poised to make a lasting impact on breast cancer treatment in China and globally.
Professor Xuepei Zhang Shares Robotic Urologic Surgery Experience from the First Affiliated Hospital of Zhengzhou University

Professor Xuepei Zhang Shares Robotic Urologic Surgery Experience from the First Affiliated Hospital of Zhengzhou University

The 2025 Annual Meeting of the Chinese Urological Association (CUDA) was held from June 12–15 in the romantic city of Zhuhai. With the theme “Healthy China, Urology in Action,” the conference brought together experts from across the country to share the latest insights and practical experience in urologic surgery. At the conference, Professor Xuepei Zhang from the First Affiliated Hospital of Zhengzhou University delivered a compelling presentation titled “Clinical Application of Robotic Combined-Approach Radical Prostatectomy,” and further shared his institution’s experience in robotic-assisted urologic procedures with UroStream.
Professor Linhui Wang: The “Changhai Experience” in Clinical Research and Practice of Urologic Oncology | CUDA 2025

Professor Linhui Wang: The “Changhai Experience” in Clinical Research and Practice of Urologic Oncology | CUDA 2025

The 2025 Annual Meeting of the Chinese Urological Doctors Association (CUDA) was successfully held from June 12 to 15 in the romantic city of Zhuhai. With the theme “Healthy China, Urology in Action,” the conference gathered urological professionals from across the country to share cutting-edge knowledge and practical experience in the field. Professor Linhui Wang from the Department of Urology at Changhai Hospital, the First Affiliated Hospital of the Naval Medical University (Shanghai), shared with Oncology Frontier – UroStream the achievements and clinical insights of his team in genitourinary oncology.